1 <u>Title:</u>

Biallelic variation in the choline and ethanolamine transporter *FLVCR1* underlies a
pleiotropic disease spectrum from adult neurodegeneration to severe developmental
disorders

5

6 Authors:

- 7 Daniel G. Calame^{1,2,3#*}; Jovi Huixin Wong^{4#}; Puravi Panda⁴; Dat Tuan Nguyen⁴; Nancy C.P.
- 8 Leong⁴; Riccardo Sangermano⁵; Sohil G. Patankar⁵; Mohamed Abdel-Hamid⁶; Lama AlAbdi^{7,8};
- 9 Sylvia Safwat⁹; Kyle P. Flannery¹⁰; Zain Dardas³, Jawid M. Fatih³; Chaya Murali³; Varun
- 10 Kannan¹; Timothy E. Lotze¹; Isabella Herman^{1,2,3,11}; Farah Ammouri^{11,12}; Brianna Rezich¹³;
- 11 Stephanie Efthymiou¹⁴; Shahryar Alavi¹⁴; David Murphy¹⁵; Zahra Firoozfar¹⁶; Mahya Ebrahimi
- 12 Nasab^{17,18}; Amir Bahreini^{19,20}; Majid Ghasemi²¹; Nourelhoda A. Haridy²²; Hamid Reza
- 13 Goldouzi²³; Fatemeh Eghbal²⁴; Ehsan Ghayoor Karimiani²⁵; Varunvenkat M. Srinivasan^{26;}
- 14 Vykuntaraju K. Gowda²⁶; Haowei Du³; Shalini N. Jhangiani²⁷; Zeynep Coban-Akdemir^{3,28}; Dana
- 15 Marafi^{3,29}; Lance Rodan^{30,31}; Sedat Isikay³²; Jill A. Rosenfeld^{3,33}; Subhadra Ramanathan³⁴;
- 16 Michael Staton³⁴; Kerby C. Oberg³⁵; Robin D. Clark³⁴; Catharina Wenman³⁶; Sam Loughlin³⁶;
- 17 Ramy Saad³⁷; Tazeen Ashraf³⁷; Alison Male³⁷; Shereen Tadros³⁷; Reza Boostani³⁸; Ghada M.H.
- 18 Abdel-Salam³⁹; Maha Zaki³⁹; Ebtesam Abdalla⁹; M. Chiara Manzini¹⁰; Davut Pehlivan^{1,2,3};
- 19 Jennifer E. Posey³; Richard A. Gibbs^{3,27}; Henry Houlden¹⁴; Fowzan S. Alkuraya^{40,41}; Kinga
- 20 Bujakowska⁵; Reza Maroofian¹⁴; James R. Lupski^{2,3,27,42*}; Long Nam Nguyen^{4,43-46*}

21

22 Author Affiliations:

 Section of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
 Texas Children's Hospital, Houston, TX, USA
 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

28 4. Department of Biochemistry, Yong Loo Lin School of Medicine, National University of 29 Singapore, Singapore 119228. 5. Ocular Genomics Institute, Department of Ophthalmology, Massachusetts Eye and Ear, 30 31 Harvard Medical School, Boston, MA 32 6. Medical Molecular Genetics Department, Human Genetics and Genome Research 33 Institute, National Research Centre, Cairo, Egypt. 34 7. Department of Zoology, College of Science, King Saud University, Rivadh, Saudi Arabia 8. Department of Translational Genomics, Center for Genomic Medicine, King Faisal 35 Specialist Hospital and Research Center, Rivadh, Saudi Arabia 36 37 9. Department of Genetics, Medical Research Institute, Alexandria University, Alexandria, 38 Egypt 39 10. Department of Neuroscience and Cell Biology, Rutgers-Robert Wood Johnson Medical 40 School, Child Health Institute of New Jersey, NY, USA 41 11. Boys Town National Research Hospital, Boys Town, NE, USA 42 12. The University of Kansas Health System, Westwood, KS, USA 43 13. Munroe-Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical 44 Center, Omaha, NE, USA 45 14. Department of Neuromuscular diseases, UCL Institute of Neurology, WC1N 3BG, 46 London, UK 47 15. Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of 48 Neurology, University College London, United Kingdom 16. Palindrome, Isfahan, Iran 49 17. Meybod Genetic Research Center, Yazd, Iran 50 51 18. Yazd Welfare Organization, Yazd, Iran 52 19. KaryoGen, Isfahan, Iran 53 20. Department of Human Genetics, University of Pittsburgh, PA, USA 54 21. Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran 55 22. Department of Neurology, Faculty of Medicine, Assiut University, Assiut, Egypt 56 23. Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, 57 Mashhad, Iran 58 24. Department of Medical Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran. 25. Molecular and Clinical Sciences Institute, St. George's, University of London, Cranmer 59 60 Terrace London, London, UK. 61 26. Department of Pediatric Neurology, Indira Gandhi Institute of Child Health, Bangalore, India 62 63 27. Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA 64 28. Human Genetics Center, Department of Epidemiology, Human Genetics, and 65 Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA 66 67 29. Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait 30. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA 68 69 31. Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, 70 USA 71 32. Gaziantep Islam Science and Technology University, Medical Faculty, Department of 72 Pediatric Neurology, Gaziantep, Turkey 73 33. Baylor Genetics Laboratories, Houston, TX, USA 74 34. Division of Genetics, Department of Pediatrics, Loma Linda University School of 75 Medicine, Loma Linda, CA, USA

76 77	35. Department of Pathology and Human Anatomy, Loma Linda University School of Medicine, Loma Linda, CA, USA
78 79	36. Rare & Inherited Disease Laboratory, NHS North Thames Genomic Laboratory Hub, Great Ormond Street Hospital for Children NHS Foundation Trust, London, WC1N 3BH,
80 81 82	37. North East Thames Regional Genetic Service, Great Ormond Street Hospital for Children NHS Foundation Trust London LIK
02 83	38 Department of Neurology Mashbad University of Medical Sciences, Mashbad, Iran
84	39 Department of Clinical Genetics, Human Genetics and Genome Research Division
85	National Research Centre, Cairo, Egypt.
86	40. Department of Translational Genomics. Center for Genomic Medicine. King Faisal
87	Specialist Hospital and Research Center, Riyadh, Saudi Arabia
88	41. Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
89	42. Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
90 91	43. Immunology Program, Life Sciences Institute, National University of Singapore, Singapore 117456.
92 93	44. Singapore Lipidomics Incubator (SLING), Life Sciences Institute, National University of Singapore, Singapore 117456.
94 95	45. Cardiovascular Disease Research (CVD) Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545
96 97	46. Immunology Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456.
98 99	# - these authors contributed equally.
100 101	* Corresponding authors: D.G.C. (<u>Daniel.calame@bcm.edu</u>); J.R.L. (jlupski@bcm.edu), L.N. (<u>bchnnl@nus.edu.sg</u>)
102	Running Title: FLVCR1-related severe neurodevelopmental disorders
103	
104	Keywords:
104 105	Keywords: FLVCR1; choline; ethanolamine; neurodevelopmental disorders; neurodegeneration; multiple
104 105 106	Keywords: FLVCR1; choline; ethanolamine; neurodevelopmental disorders; neurodegeneration; multiple congenital anomalies; Diamond-Blackfan anemia
104 105 106 107	Keywords: FLVCR1; choline; ethanolamine; neurodevelopmental disorders; neurodegeneration; multiple congenital anomalies; Diamond-Blackfan anemia
104 105 106 107 108	Keywords: FLVCR1; choline; ethanolamine; neurodevelopmental disorders; neurodegeneration; multiple congenital anomalies; Diamond-Blackfan anemia
104 105 106 107 108 109	Keywords: FLVCR1; choline; ethanolamine; neurodevelopmental disorders; neurodegeneration; multiple congenital anomalies; Diamond-Blackfan anemia
104 105 106 107 108 109 110	Keywords: FLVCR1; choline; ethanolamine; neurodevelopmental disorders; neurodegeneration; multiple congenital anomalies; Diamond-Blackfan anemia
104 105 106 107 108 109 110 111	Keywords: FLVCR1; choline; ethanolamine; neurodevelopmental disorders; neurodegeneration; multiple congenital anomalies; Diamond-Blackfan anemia
104 105 106 107 108 109 110 111 112	Keywords: FLVCR1; choline; ethanolamine; neurodevelopmental disorders; neurodegeneration; multiple congenital anomalies; Diamond-Blackfan anemia

114 Abstract:

FLVCR1 encodes Feline leukemia virus subgroup C receptor 1 (FLVCR1), a solute carrier (SLC) transporter within the Major Facilitator Superfamily. FLVCR1 is a widely expressed transmembrane protein with plasma membrane and mitochondrial isoforms implicated in heme, choline, and ethanolamine transport. While *Flvcr1* knockout mice die *in utero* with skeletal malformations and defective erythropoiesis reminiscent of Diamond-Blackfan anemia, rare biallelic pathogenic *FLVCR1* variants are linked to childhood or adult-onset neurodegeneration of the retina, spinal cord, and peripheral nervous system.

122 We ascertained from research and clinical exome sequencing 27 individuals from 20 123 unrelated families with biallelic ultra-rare missense and predicted loss-of-function (pLoF) 124 FLVCR1 variant alleles. We characterize an expansive FLVCR1 phenotypic spectrum ranging 125 from adult-onset retinitis pigmentosa to severe developmental disorders with microcephaly. 126 reduced brain volume, epilepsy, spasticity, and premature death. The most severely affected 127 individuals, including three individuals with homozygous pLoF variants, share traits with Flvcr1 128 knockout mice and Diamond-Blackfan anemia including macrocytic anemia and congenital 129 skeletal malformations. Pathogenic FLVCR1 missense variants primarily lie within 130 transmembrane domains and reduce choline and ethanolamine transport activity compared with 131 wild-type FLVCR1 with minimal impact on FLVCR1 stability or subcellular localization. Several 132 variants disrupt splicing in a mini-gene assay which may contribute to genotype-phenotype 133 correlations. Taken together, these data support an allele-specific gene dosage model in which 134 phenotypic severity reflects residual FLVCR1 activity. This study expands our understanding of 135 Mendelian disorders of choline and ethanolamine transport and demonstrates the importance of 136 choline and ethanolamine in neurodevelopment and neuronal homeostasis.

137

138

139 <u>Text:</u>

140 Solute transport across lipid bilayers is critical for biological homeostasis and requires specialized transmembrane proteins¹. The largest group of membrane transport proteins is the 141 142 solute carrier (SLC) superfamily. The superfamily consists of 458 genes divided into 65 143 families¹. SLC proteins transport a vast assortment of solutes including amino acids, sugars, 144 ions, nucleotides, vitamins, and neurotransmitters. Genetic variation in SLC genes influences common diseases, metabolic traits, and an expanding spectrum of Mendelian disorders²⁻⁴. As 145 146 solute transport disorders are responsive to solute supplementation, dietary interventions, and gene therapies in preclinical models and humans, they are attractive therapeutic targets^{5–7}. Yet, 147 148 the function of most SLC genes in human biology remains poorly characterized.

149 One SLC family member associated with Mendelian neurodegenerative disorders is 150 FLVCR1 (also known as SLC49A1 and MFSD7B). First recognized as the receptor for Feline 151 Leukemia Virus Subgroup C (FeLV-C), a retrovirus which causes aplastic anemia in cats⁸. 152 FLVCR1 is highly conserved and encodes two isoforms in humans: a full-length 555 amino acid 153 (aa) plasma membrane isoform FLVCR1a and a small mitochondrial membrane isoform 154 FLVCR1b (aa 277-555)⁹. FLVCR1 was initially described as a heme exporter in ervthroid cells. and other cell lineages¹⁰. An essential requirement for FLVCR1 was subsequently demonstrated 155 through knockout of the mouse ortholog *Flvcr1*¹¹. Germline knockout of *Flvcr1* results in 156 157 embryonic lethality, absent erythropoiesis, craniofacial and limb malformations, and hepatic iron accumulation, whereas neonatal deletion causes severe macrocytic anemia¹¹. Both FLVCR1 158 159 isoforms are required for murine viability; mice retaining FLVCR1b but lacking FLVCR1a have normal erythropoiesis but develop hemorrhages, edema, and skeletal malformations⁹. The 160 161 physiologic significance of FLVCR1 heme transport has been called in guestion especially 162 considering recent evidence that FLVCR1 is a choline and ethanolamine transporter^{4,12–16}.

163 The severe anemia and craniofacial, limb and digital malformations in *Flvcr1* knockout mice resemble humans with Diamond-Blackfan anemia (DBA) [MIM: 105650]^{11,17}. A further link 164 165 between FLVCR1 and DBA was suggested by the observation that FLVCR1 splicing is dysregulated in erythroid cells from patients with DBA¹⁸. However, biallelic variation in *FLVCR1* 166 167 has not been identified in individuals with DBA, and DBA is now recognized as primarily a disorder of ribosome biogenesis¹⁷. Instead, biallelic pathogenic variation in *FLVCR1* causes rare 168 169 recessive neurodegenerative disorders of the retina, spinal cord, and peripheral nerves: 170 posterior column ataxia with retinitis pigmentosa (PCARP) [MIM: 609033], isolated retinitis pigmentosa (RP), and hereditary sensory and autonomic neuropathy (HSAN)¹⁹⁻²¹. FLVCR1-171 172 related neurodegenerative disorders can manifest from childhood into adulthood. To date, at 173 least 39 individuals from 22 families have been identified with FLVCR1-related 174 neurodegeneration; most have biallelic FLVCR1 missense variants, and predicted loss-of-175 function variants have only been identified in trans with missense variants (Supplemental 176 Table S1). Despite the severe multi-organ consequences of Flvcr1 knockout in mice, extra-177 neurological findings or severe developmental disorders have only been described in one 178 individual with biallelic FLVCR1 variants, a compound heterozygote (c.574T>C p.Cys192Arg; c.610del p.Met204Cysfs*56) with severe developmental disabilities, chronic macrocytic anemia, 179 liver disease, self-mutilation, and sensory neuropathy²¹. The precise reason(s) for the apparent 180 181 discrepancies between human and mouse FLVCR1-related phenotypes remains unclear but 182 could suggest that FLVCR1 knockout is incompatible with human life.

The index case who initiated this study is a male child with severe developmental delay, epileptic encephalopathy, and microcephaly (Individual 1, **Fig. 1, Fig. 2A-E**, **Table 1**). He was born to non-consanguineous parents from a country in South Asia. He had a history of infantile spasms, self-mutilation, osteomyelitis, and absent sensory nerve responses on nerve conduction studies. Brain magnetic resonance imaging (MRI) showed corpus callosum thinning,

188 brainstem and pontine thinning, prominent extra-axial fluid spaces, and reduced white matter 189 volume (Fig. 2A-E). Uric acid and purine levels, measured to assess for Lesch-Nyhan 190 syndrome [MIM: 300322] due to the history of severe self-injury, were normal. Clinical trio 191 exome sequencing (cES) did not identify any variants in HPRT1 nor pathogenic variants in 192 known disease genes. Hence, these cES data underwent research reanalysis through the 193 Baylor College of Medicine Genomics Research Elucidates the Genetics of Rare diseases 194 (BCM-GREGoR) which prioritized the homozygous FLVCR1 missense variant c.1390G>A 195 p.G464S given the overlap between the patient's known sensory neuropathy and known 196 FLVCR1-related disorders.

197 To comprehensively characterize the phenotypic spectrum of FLVCR1-related disorders 198 in humans, we reanalyzed ES and genome sequencing (GS) data from the 29,766 individuals within the BCM-GREGoR and Baylor Genetics clinical diagnostic databases²², utilized the online 199 matchmaking program GeneMatcher^{23,24}, and searched other research and diagnostic lab 200 201 datasets. We identified 27 individuals from 20 unrelated families with neurological disorders and 202 biallelic FLVCR1 variants (Fig. 1, Table 1). A pedigree was not available for Individual 27, an 203 elderly woman with isolated retinitis pigmentosa and dystonia. Unlike prior reports describing 204 biallelic FLVCR1 variants in children or adults with neurodegenerative disorders, Individuals 1-205 17 had severe developmental disorders. Notably, three individuals with severe developmental 206 disorders had homozygous FLVCR1 pLoF variants (Individuals 4, 15, and 17). Individuals 18-27 207 had childhood or adult-onset neurodegenerative disorders including PCARP, hereditary spastic 208 paraplegia, and RP (**Table 1**). Most families (14/20) are consanguineous by clinical history. In 209 Families 1 and 7, the same homozygous missense variant c.1390G>A p.G464S was identified. 210 Both families originate in the same country in South Asia and are unrelated. Neither family are 211 consanguineous by clinical history. Absence-of-heterozygosity (AOH), a surrogate measure from ES data for runs-of-homozygosity (ROH), was calculated for Family 1; total autosomal 212

AOH was 150.1 Mb, and the variant was surrounded by a 4.9 Mb AOH block (Supplemental
Fig. 1)²⁵. These data suggest *FLVCR1*: c.1390G>A p.G464S may represent a South Asian
founder allele. Compound heterozygous variants were identified in the three nonconsanguineous families and segregated according to Mendelian expectations within Family 8.
All clinical and research data were acquired in accordance with ethical standards upon informed
consent and with the approval of the collaborative institutional review boards (Supplemental
Methods).

220 The phenotypic features of the 27 individuals are summarized in Table 1, Fig. 2, and 221 Supplemental Table 1. Individuals 1-17 exhibited severe developmental delay: all were non-222 verbal and achieved no developmental motor milestones. All were microcephalic (median Z-223 score -4.45, range -2.5 to -10.5) and had reduced brain volume on brain magnetic resonance 224 imaging (MRI). Individual 16 was microcephalic at birth (29 cm, Z-score -3.9) but was 225 normocephalic at 3 years old (50.2 cm, Z-score +1.05). Brain MRI findings varied considerably. 226 Some individuals had only a mild reduction in white matter volume, corpus callosum thinning, 227 and/or pontine and brainstem thinning (**Fig. 2E**). Others had a severe reduction in brain volume 228 with simplified gyral pattern (Fig. 2H, J, K). In Family 8, cystic encephalomalacia was seen in all 229 three affected siblings (Fig. 20-R); cystic encephalomalacia was detected on fetal MRI 230 suggesting a very early developmental defect. Individuals 16 and 17 had only a thin rim of 231 cerebral cortex reminiscent of hydrancephaly. Another recurring MRI finding observed in 232 Individuals 1 and 3 was T2 hyperintensity of the posterior columns on spine MRI as previously 233 reported in PCARP (Fig. 2L). Premature death before adulthood was common (14/17). 234 Hypotonia and epilepsy were nearly universal in individuals who survived the neonatal period. 235 Other common traits include cortical visual impairment, optic disk atrophy, and spasticity. 236 Features previously associated with FLVCR1 including RP and sensory neuropathy were 237 observed but uncommon; this could represent age-dependent penetrance due to the young age

of the cohort or under-ascertainment. Individuals 1 and 8 with the homozygous p.G464S variant
had a history of self-mutilation, osteomyelitis, and sensory neuropathy; congenital insensitivity to
pain was reported in Individual 3, but nerve conduction studies were not performed. Individual
16 also engaged in self-injurious behavior including tongue and lip biting.

242 The most profoundly affected individuals exhibited considerable phenotypic overlap with 243 *Flvcr1* knockout mice. Individuals 9-11 in Family 8 were stillborn and exhibited craniofacial, limb, 244 and digital malformations; they were recently identified in a large cohort that investigated the 245 utility of long-read whole genome sequencing²⁶ (Fig. 2X-g, Supplemental Data). Individual 17 246 from Family 12 died on in the neonatal period. Fetal MRI and autopsy demonstrated 247 craniofacial, limb, and digital malformations in addition to congenital heart disease, renal 248 agenesis, hepatosplenomegaly, and paper-thin cerebral cortex with hydrocephalus and multiple 249 hemorrhages (Fig. 2X-d, Supplemental Data). Bone marrow hematopoiesis was normal. 250 Hepatomegaly and milder digital malformations including polydactyly and arthrogryposis were 251 also observed in other individuals with FLVCR1-associated severe developmental disorders. 252 Unexplained macrocytic anemia was present in 5 of 12 individuals who survived the neonatal 253 period and for whom red blood cell studies were performed. Reduced fetal movements were reported in Families 8 and 11. 254

255 Families 13-20 had mild *FLVCR1*-related diseases including typical phenotypes 256 (PCARP, HSAN, RP) as well as developmental delay and the novel phenotype hereditary 257 spastic paraplegia. While spasticity is a common feature of severe FLVCR1-related developmental disorders, it is uncommon in mild *FLVCR1*-related disease²⁷. Two recurrent 258 259 variants, p.Y128N and p.I343T, were observed in unrelated Persian families. Brain MRI was not 260 performed in most instances of mild FLVCR1-related disease but was normal in individual 20 261 with *FLVCR1*-related sensory neuropathy, RP, and mild intellectual disability. The two siblings in 262 Family 17 were evaluated for developmental delay, microcephaly, hypotonia, and hyporreflexia.

263 There was intrafamilial variability with the younger brother exhibiting more developmental 264 impairment than the older brother (Supplemental Fig. 2). In Family 18, the young adult 265 asymptomatic sister of Individual 25 was also homozygous for FLVCR1: c.502C>G p.L168V; as 266 age of onset as late as the third or fourth decade of life has been described, this likely represents age-related penetrance²⁸. 267 268 Twenty FLVCR1 variants were identified within the cohort; only two, c.1593+5 1593+8del and c.574T>C p.C192R were previously reported (**Table 2**)^{19,29}. 269 270 FLVCR1(NM 014053.4) consists of 10 exons and encodes a protein with 12 transmembrane 271 domains. We visualize the distribution of reported pathogenic FLVCR1 variants within the

272 *FLVCR1*(NM_014053.4) cDNA and protein (**Fig. 3A,B**). All pathogenic *FLVCR1* variants are

rare and absent in the homozygous state in gnomAD v2.1.1³⁰. Most are predicted damaging by

274 multiple pathogenicity predictors and affect conserved residues (**Table 2, Supplemental Table**

1). Amino acid substitutions within FLVCR1 transmembrane domains are predicted damaging

by the protein language model ESM1b³¹, and nearly all pathogenic *FLVCR1* missense variants

fall within well-conserved transmembrane domains (Fig. 3B; Supplemental Fig. 4). All FLVCR1

278 nonsense and frameshift variants are predicted to trigger nonsense-mediated decay (NMD)³².

279 To assess the impact of c.884-3C>G on splicing, whole blood RNA was isolated from the carrier

280 mother of Individual 16, and reverse transcriptase polymerase chain reaction (RT-PCR) was

281 performed. RT-PCR produced two bands: a larger band seen in controls and a smaller band

absent in controls (**Supplemental Fig. 4**). Sanger sequencing confirmed that the larger band

283 represented wild-type *FLVCR1*, whereas the smaller band represented a heterozygous deletion

of exon 3 (r.884_1024del, p.A295_Y341del). The deletion spans portions of transmembrane

domains 6 and 7 and completely removes the fourth cytoplasmic loop (**Fig. 3B**). The splicing

variant c.1593+5_1593+8del is strongly predicted to alter splicing by SpliceAI (donor loss Δ

score 0.97) and Pangolin (splice loss Δ score 0.88). A mini-gene splicing assay confirmed this

variant causes exon 9 skipping which is predicted to result in protein truncation

289 (r.1526_1593del; p.A509Dfs*4) (**Supplemental Fig. 5 & 9**).

290 Pathogenic missense variants are anticipated to disrupt gene function and involve more 291 highly conserved functional regions than benign missense variants within the human population 292 and non-human primates. We therefore compared pathogenicity predictions and conservation 293 metrics between FLVCR1 missense variants identified in individuals with FLVCR1-related 294 disorders and FLVCR1 missense variants present in human and primate populations in 295 gnomAD v2.1.1 and primAD v1.0 (Fig. 3C)^{30,33}. CADD, REVEL, MetaRNN, phyloP100way, and 296 GERP scores were all significantly greater in cases than controls. In contrast, there was no 297 difference in CADD, REVEL, or GERP scores between missense variants identified in mild 298 versus severe FLVCR1-related disorders (Fig. 3D). Comparison of the distribution of severe 299 versus mild disease-associated missense variants demonstrated that severe disease-300 associated missense variants form a cluster within transmembrane domains 9-11 (5 of 8 severe 301 disease-associated variants vs. 0 of 15 mild disease-associated variants). Similarly, 87.5% of 302 severe disease-associated missense variants (7/8) lie within both the plasma membrane 303 isoform FLVCR1a and the mitochondrial isoform FLVCR1b, whereas only 53.3% of mild 304 disease-associated missense variants (8/15) fell within both isoforms.

305 To investigate the molecular consequence of FLVCR1 missense variants on gene 306 function, we generated missense variants using site-directed mutagenesis of human FLVCR1 cDNA and examined each variant's choline and ethanolamine transport activity (Fig. 4)¹⁴. 307 308 Briefly, human FLVCR1 cDNA was co-transfected into HEK293 cells along with human choline 309 kinase A (CHKA) or ethanolamine kinase 1 (ETNK1) cDNA because the sole expression of 310 FLVCR1 cDNA only slightly increased choline or ethanolamine transport activity. HEK293 cells 311 were then incubated with [³H] choline or [¹⁴C] ethanolamine, washed, and cellular radioactivity 312 levels were measured. CHKA catalyzes choline phosphorylation into phosphocholine while

313 ETNK1 catalyzes ethanolamine into phosphatidylethanolamine; their co-expression along with FLVCR1 greatly increases choline or ethanolamine import¹⁴. In addition to the FLVCR1 314 315 missense variants identified in this publication, we also examined p.Q124L and p.G219C, two 316 FLVCR1 variants recently identified in an individual with HSAN^{19,34}. These assays demonstrated 317 nearly all FLVCR1 missense variants significantly reduced choline and ethanolamine transport 318 activity relative to wild-type FLVCR1 with transport activity ranging from 0% to 55.38% (choline) 319 and 0% to 48.80%. The transport activity of two variants, p.M151V and p.D421N, was 320 comparable to wild-type FLVCR1. The p.M151V variant occurred in the homozygous state in an 321 individual within the BCM-GREGoR database. This individual had a blended developmental 322 disorder phenotype resulting from multi-locus pathogenic variation in three genes: AP4B1, 323 AMPD2, and NOTCH2³⁵. As the individual's phenotype is explained by other gene variants and 324 the p.M151V variant's transport activity is normal, p.M151V may represent a rare benign 325 polymorphism. The p.D421N variant was identified in compound heterozygosity with a 326 nonsense variant in Individual 3. Although p.D421N did not alter choline or ethanolamine 327 transport activity, the variant is weakly predicted to cause donor loss by SpliceAI (score 0.22). A 328 mini-gene splicing assay of this variant (c.1261G>A p.D421N) demonstrated a strong effect on 329 exon 6 skipping (Supplemental Fig. 5 & 6). The phenotypic overlap of Individual 3 with other 330 severe FLVCR1 cases and the presence of typical FLVCR1 features including RP and posterior 331 column T2 hyperintensity supports the variant's pathogenicity. Another missense variant in the 332 same exon (c.1235G>A p.G412A) also showed a strong effect on exon 6 skipping in addition to 333 its effect on choline and ethanolamine transport (Supplemental Fig. 5 & 6). Western blot 334 analysis of HEK293 cells overexpressing wild-type and variant FLVCR1 showed similar levels of 335 FLVCR1 protein indicating that FLVCR1 missense variants do not impact protein stability (Fig. 336 4). Immunostaining demonstrates FLVCR1 missense variants localize to the plasma membrane 337 like wild-type FLVCR1; only p.G412A exhibited abnormal intracellular accumulation (Fig. 4). As 338 we previously characterized the choline transport activity of all FLVCR1 missense variants

reported in the literature³⁶, we compared transport activity between mild and severe phenotypeassociated variants but found no significant difference (mean choline transport activity as a percentage of wild-type FLVCR1: mild phenotypes, 34.3 ± 21.9 ; severe phenotypes, 35.5 ± 21.9 ; p=0.9222).

343 Here, we demonstrate rare genetic variation in the choline and ethanolamine transporter 344 gene FLVCR1 causes a broad and pleiotropic recessive disease spectrum ranging from adult 345 neurodegeneration to severe developmental disorders. Choline is an essential nutrient which 346 plays an integral role in methyl group metabolism, phosphatidylcholine (PC) synthesis via the Kennedy pathway, and acetylcholine synthesis³⁷. While *de novo* choline synthesis occurs in the 347 348 liver through the phosphatidylethanolamine N-methyltransferase pathway, this pathway is inadequate to meet the needs of the human organism³⁷. Choline is found in animal products, 349 cruciferous vegetables, and beans³⁷. The dietary intake of choline in most individuals in the 350 351 United States and Europe falls below the United States Institute of Medicine's adequate intake level^{37,38}. Choline insufficiency is particularly common in low-income countries, and choline is 352 neglected in nutrient-fortified food aid³⁹. Furthermore, individual dietary requirements vary 353 354 considerably due to multiple factors including genotype, sex, developmental stage, and dietary intake of vitamins involved in methyl group metabolism including folate and B12⁴⁰. Single 355 356 nucleotide polymorphisms in genes involved in the phosphatidylethanolamine N-357 methyltransferase pathway, folate and methyl group metabolism, and choline transport including 358 PEMT, MTHFR, MTR, MTRR, and SLC44A1 have been shown to modulate choline requirements and risk of choline deficiency⁴⁰. Similarly, ethanolamine cannot be synthesized in 359 360 humans and is a precursor for phosphatidylethanolamine (PE) synthesis via the Kennedy 361 pathway⁴¹. PE and PC are abundant membrane phospholipids required for membrane integrity, 362 cell division, and mitochondrial respiratory function.

Choline is required for normal neurodevelopment⁴². Maternal choline deficiency impairs 363 364 hippocampal development as well as neuronal progenitor cell and retinal progenitor cell expansion and differentiation in mouse embryos^{43,44}. Choline deficiency also causes anemia, 365 liver disease, growth retardation, and immune deficiency^{45–47}. Neurodevelopment is also 366 disrupted by defective choline uptake⁴⁸. Pathogenic variation in *SLC5A7*, the gene encoding a 367 368 high affinity choline transporter expressed in cholinergic neurons, causes two 369 neurodevelopmental disorders: autosomal recessive (AR) presynaptic congenital myasthenic 370 syndrome 20 [MIM: 617143] and autosomal dominant (AD) distal hereditary motor neuronopathy [MIM: 158580]^{49,50}. Similarly, pathogenic variation in *SLC44A1*, a gene predicted 371 372 to encode the low affinity choline transporter CTL1, causes AR childhood-onset neurodegeneration with ataxia, tremor, optic atrophy, and cognitive decline [MIM: 618868]⁵¹. 373 374 Finally, the protein encoded by closely related gene FLVCR2 is expressed at the blood-brain barrier and transports choline and ethanolamine^{16,52}. Pathogenic variation in *FLVCR2* causes 375 376 Fowler syndrome, a severe AR disorder characterized by proliferative vasculopathy, hydranencephaly, fetal akinesia deformation sequence, and prenatal lethality [MIM: 225790]⁵³. 377 378 The identification of *FLVCR1* as a neurodevelopmental choline and ethanolamine transport 379 disorder further reinforces the critical role of choline and ethanolamine in brain development. 380 Additionally, the identification of multiple neurodevelopmental choline and ethanolamine 381 transport disorders demonstrates considerable complexity to choline and ethanolamine 382 regulation within the developing brain and warrants further study. Therapeutic choline and 383 ethanolamine supplementation has not been attempted in patients with choline and 384 ethanolamine transport disorders but could in theory be efficacious as in riboflavin transporter deficiency⁶. The existence of multiple choline transporters allows for alternative routes for 385 386 choline uptake¹, and supplementation could potentially boost choline intake through 387 hypomorphic transporters. Randomized controlled trials of choline supplementation in fetal 388 alcohol syndrome have shown choline supplementation is well-tolerated and can have beneficial

neurocognitive effects^{54,55}. Measurement of choline and ethanolamine levels in biospecimens
 from individuals with *FLVCR1*-related disorders is needed to inform choline and/or ethanolamine
 supplementation as a potential therapeutic modality.

392 Based on these findings, we propose an allele-specific gene dosage model in which 393 disease severity is a function of residual FLVCR1 activity. This proposal stems from three key 394 observations. First, we identified three individuals with severe developmental disorders and 395 homozygous FLVCR1 pLoF variants. These individuals are thus genetically equivalent to Flvcr1 396 knockout mice and zebrafish, which also exhibit severe developmental phenotypes^{11,56}. Biallelic 397 pLoF FLVCR1 variants have not been identified in individuals with milder FLVCR1-related 398 phenotypes like PCARP; nearly all reported individuals instead have biallelic missense variants. 399 Second, we show most pathogenic FLVCR1 missense variants reduce but do not completely eliminate choline and ethanolamine transport and thus likely represent hypomorphic alleles³⁶. 400 401 *Flvcr1* was previously shown to exhibit highest central nervous system expression in the retina 402 followed by the posterior column of the spinal cord and cerebellum; this may parsimoniously explain the susceptibility of these tissues to mild hypomorphic alleles¹⁹. Third, we observe 403 404 evidence of complex compound inheritance in which FLVCR1 variants may contribute to mild 405 phenotypes in homozygosity but severe phenotypes in compound heterozygosity with a more 406 severe variant (e.g., FLVCR1 p.C192R) or severe phenotypes in homozygosity but mild 407 phenotypes when paired with a less deleterious variant (e.g., FLVCR1 408 c.1593+5 1593+8del)^{19,21,29}. The allele-specific gene dosage model is well-described in 409 recessive disorders but can confound diagnostic personalized genome analysis when the 410 clinically reported phenotype diverges substantially from the disease trait clinical synopsis 411 provided in the literature or online databases like Online Mendelian Inheritance in Man (OMIM). 412 Indeed, the severely affected individuals reported here had all undergone clinical or research 413 exome or genome sequencing which identified the reported FLVCR1 variants, yet in each case

the variants were previously felt either non-contributory or of uncertain significance given the
apparent phenotypic mismatch. Such false assumptions illustrate the importance of
incorporating model organism data into personalized genome analysis for rare diseases and the
need to anticipate more severe and milder phenotypes associated with each disease gene locus
to maximize the yield of diagnostic genetic testing.

419 We did not observe a correlation between FLVCR1 missense variant choline transport 420 activity and phenotypic severity in our functional assay. There are several possible 421 explanations. First, our choline transport assay may lack the sensitivity to discriminate between 422 mild and severe phenotype-associated variants. As the transport assay is reliant on 423 overexpression of FLVCR1 cDNA, it is insensitive to splicing defects. Indeed, we demonstrate 424 through mini-gene splicing assays that several *FLVCR1* single nucleotide variants and indels 425 disrupt splicing (Supplemental Figures 5-9). Second, the cellular phenotype assessed by the 426 choline transport assay must be distinguished from the organismal phenotypes characterized in 427 humans with pathogenic FLVCR1 variation. Third, FLVCR1 was found to transport additional ligands like ethanolamine in both this study and previous studies¹⁴. While a reduction in both 428 429 choline and ethanolamine transport was observed with most variants, some like p.S305R had a 430 more severe impact on ethanolamine than choline transport. Fourth, as both plasma membrane and mitochondrial isoforms FLVCR1a and FLVCR1b are required for murine viability⁹, a 431 432 missense variant involving both isoforms may have a greater phenotypic impact than one only 433 impacting the plasma membrane isoform FLVCR1a. In line with this hypothesis, we observed 434 nearly all severe disease associated FLVCR1 missense variants are predicted to impact both 435 isoforms. Another possibility is maternal and/or fetal deficiency of choline, ethanolamine, folate, 436 and/or B12 due to poor dietary intake or maternal-fetal genotypes could act as phenotypic modifiers⁴⁰. Finally, it is important to note the phenotypes associated with homozygous first 437 438 exon frameshifts in Individuals 4 and 15 were not as severe as those seen in Individual 17 with

the homozygous exon 4 nonsense variant nor in individuals 12-14 with the homozygous splice
site variant c.1593+5_1593+8del. This defines a gene polarity effect⁵⁷. One possible explanation
is first exon pLoF variants may not represent true null alleles. First exon premature termination
codons (PTCs) can escape NMD and generate a functional or partially functional truncated
protein if a downstream methionine allows for in-frame translation re-initiation⁵⁸.

444 In summary, our report reveals a broad and pleiotropic phenotypic spectrum resulting 445 from biallelic FLVCR1 variants; these range from adult neurodegeneration to severe 446 developmental disorders with variable anemia and skeletal malformations. Combined with recent studies demonstrating FLVCR1 encodes a choline and ethanolamine transporter^{4,13,16,36}, 447 448 these data suggest choline and ethanolamine transport into the central and peripheral nervous 449 systems is essential to prevent neurodegeneration and required for neurodevelopment. The 450 observation that the most severe FLVCR1-related phenotypes cause stillbirth and resemble 451 Diamond-Blackfan anemia establishes FLVCR1 should be considered in the differential 452 diagnosis of recurrent miscarriage, multiple congenital anomalies, and severe Diamond-453 Blackfan anemia-like phenotypes. Further studies are required to understand the impact of gene 454 x environmental (GxE) interactions on FLVCR1-related phenotypes and the therapeutic 455 implications of choline or ethanolamine supplementation in *FLVCR1*-related diseases. 456 457 **Figure Legends:**

458 Figure 1: Pedigrees of families with *FLVCR1*-related developmental and

459 neurodegenerative disorders.

460 Per medrxiv requirements, this figure was removed but is available upon request to the
 461 corresponding authors.

462 Pedigrees of families with *FLVCR1*-related diseases. Genotype is indicated above each 463 pedigree and below each family member. *A* indicates wild-type *FLVCR1* allele, *a* indicates

464 *FLVCR1* variant allele 1, and *a'* indicates *FLVCR1* variant allele 2; specific variants differ from 465 one pedigree to the next. Red shading indicates severe *FLVCR1*-related disease (microcephaly, 466 brain atrophy, severe developmental disabilities), whereas light blue shading indicates relatively 467 milder neurological *FLVCR1*-related disease (posterior column ataxia with retinitis pigmentosa, 468 hereditary sensory and autonomic neuropathy, isolated retinitis pigmentosa, or hereditary 469 spastic paraplegia). Gray shading indicates individuals suspected of possibly having a different 470 genetic syndrome characterized by neonatal demise, hypotonia, and arthrogryposis.

471

472 Figure 2: Phenotypic features of *FLVCR1*-related developmental and neurodegenerative 473 disorders

Photographs and magnetic resonance imaging (MRI) from each family are divided into separate
boxes bordered by thin black lines. Per medrxiv requirements, patient photographs have
been removed but are available upon request to the corresponding authors.

A-E) Images of Individual 1 (I-1), Family 1 with homozygous *FLVCR1* p.G464S variant. A-D
show examples of self-mutilation including foot, ear, and arm ulcerations (yellow arrowheads)
and digital amputation (red arrowhead). E shows sagittal T1-weighted brain MRI. Pontine
thinning is indicated with yellow arrow.

F) Image of Individual 8 (I-8), Family 7 with homozygous *FLVCR1* p.G464S variant. Selfmutilation and digital amputation of the hand is shown.

G, H) Images of Individual 2 (I-2), Family 2. G shows patient with triangular facies, microcephaly
and severe developmental delay. H shows axial T2-weighted brain MRI demonstrating severe
reduction in cerebral brain volume and a simplified gyral pattern.

486 I, J) Images of Individual 5 (I-5), Family 5. I shows patient with microcephaly, broad nasal
487 bridge, widely spaced eyes, and severe developmental delay. J shows axial T1-weighted brain
488 MRI, demonstrating severe reduction in cerebral brain volume and a simplified gyral pattern.

K, L) Images of Individual 3 (I-3), Family 3. K shows axial T2-weighted brain MRI with severe
 reduction in cerebral brain volume. L shows T2-weighted cervical spine MRI demonstrating
 posterior column T2 signal hyperintensity (red arrow).

492 M-R) Images of Individuals 10 and 11 (I-10 and I-11), Family 8. M and N show individuals 10 493 and 11. Photographs demonstrating microcephaly, severe developmental delay, broad nasal 494 bridge, and tracheostomy secondary to respiratory failure. O-R show axial T1-weighted brain 495 MRI from Individual 11 demonstrating reduction in cerebral brain volume with relative cerebellar 496 sparing and cystic encephalomalacia (red arrows).

497 S-U) Images of Individual 7 (I-7), Family 6. Images show axial T2-weighted brain MRI with
498 reduction in cerebral brain volume.

V, W) Images of Individual 16 (I-16), Family 11. V and W show coronal T2-weighted brain MRI
and axial T1-weighted brain MRI respectively demonstrating a severe reduction in brain volume
with hydrocephalus *ex vacuo*.

502 X-d) Images of Individual 17 (I-17), Family 12. X shows irregular undulation of the ear lobe. Y shows the left foot with ankle dislocation and absence of the great toe, 2nd toe, and 3rd toe. Z 503 shows the right foot demonstrating cleft foot, absence of the 2nd toe, syndactyly of toes 3-4, and 504 505 proximal displacement of the great toe. a is a full body radiograph demonstrating ten ribs, long 506 limbs, absent left tibia (red arrow), and bilateral ectrodactyly of the feet. b-d are fetal T2-507 weighted MRI images performed at 28 weeks gestation. b shows hydrocephalus with absence 508 of midline structures (blue arrow) and hypertrophic kidney with pelviectasis (red arrow). c shows 509 hydrocephalus with absence of some midline structures (red arrow) and thinning of the cortical

510 mantle (blue arrow). d shows severe hydrocephalus with thinning of the cortical mantle (red 511 arrow), small cerebellum and brainstem (blue arrow), and left kidney hypertrophy with absence 512 of the right kidney (yellow arrow).

e-g) Images of Individual 13 (I-13), Family 9. Postmortem images of Individual 13 (c-e) show
joint contractures, long tapering figures. absent right thumb, hypoplastic left thumb,
microcephaly, and cleft lip and palate.

516 Figure 3: Summary of the FLVCR1 allelic series

A) Model of protein-coding portions of human *FLVCR1* cDNA (NM_014053.4) showing location of novel and previously published start loss variants, splicing variants, nonsense variants, and frameshift variant alleles. Start loss and splicing variants are indicated by arrowheads above the model. Nonsense and frameshift variants are indicated by arrowheads below the model. Red arrowheads show variants associated with severe phenotypes, whereas light blue shading indicates the relatively milder neurological disease.

523 B) Model of human FLVCR1 protein (Uniprot entry Q9Y5Y0) showing location of novel and 524 previously published missense variants. Light gray rectangles indicate transmembrane domains, 525 dark gray rectangles indicate intracellular domains, and dark blue rectangles indicate 526 extracellular domains. Red ball and sticks indicate severe phenotypes, whereas light blue ball 527 and sticks indicate mild phenotypes. Portions of FLVCR1 found within the plasma membrane 528 isoform FLVCR1a and mitochondrial isoform FLVCR1b are indicated below the figure in green 529 and purple, respectively. Red box indicates region deleted due to c.884-3C>G (r.884 1024del, 530 p.A295 Y341del). ESM1b pathogenicity predictions are shown above the model. Increasing 531 likelihood of pathogenicity is reflected by the blue (low) to yellow (high) gradient.

532 **C)** Comparison of pathogenicity predictions (CADD, REVEL, MetaRNN) and conservation 533 metrics (phyloP100way, GERP) between novel and previously reported pathogenic *FLVCR1*

variants and all variants within gnomAD v3.1.2 (76,156 human samples, 189 variants) and primateseq v1.0 (811 primate samples from 236 primate species, 209 variants). * p<0.05, unpaired t test with Welch's correction.

D) Comparison of pathogenicity predictions (CADD, REVEL) and conservation metric (GERP) between mild and severe *FLVCR1*-related phenotypes. Differences in transmembrane domains 9-11 and isoform clustering of *FLVCR1* variants between mild and severe phenotypes is also displayed. Gray = variants located outside transmembrane domains 9-11, black = variants located inside transmembrane domains 9-11, purple = variants located inside mitochondrial isoform FLVCR1b, green = variants located inside plasma membrane isoform FLVCR1a but not FLVCR1b. ns = not significant, TM = transmembrane.

544

545 **Figure 4: Pathogenic missense variation in** *FLVCR1* reduces choline and ethanolamine 546 transport

A-B) Choline transport activity of the FLVCR1 missense variants expressed as absolute values
(DPM/well) or as percentage of wildtype (WT) FLVCR1. These missense variants and WT
human FLVCR1 (hFLVCR1) were co-expressed with choline kinase alpha (CHKA) in HEK293
cells for activity assay with [3H] choline. Mock was transfected with CHKA alone. Experiments
were performed at least twice in triplicates. Data are expressed as mean ± SD. ****P<0.0001;
One-way ANOVA for A-B. ns, not significant.

C-D) Ethanolamine transport activity of the FLVCR1 missense variants expressed as absolute
 values (DPM/well) or as percentage of WT FLVCR1. These missense variants and WT human
 FLVCR1 were co-expressed with ethanolamine kinase 1 (ETNK1) in HEK293 cells for activity
 assay with [14C] ethanolamine. Mock was transfected with ETNK1 alone. Experiments were

- 557 performed at least twice in triplicates. Data are expressed as mean ± SD. ****P<0.0001; One-
- 558 way ANOVA for C-D. ns, not significant.
- 559 E) Western blot analysis of HEK293 cells overexpressed with WT or hFLVCR1 variants. Red
- 560 vertical arrowhead marks M_r = 59 kD migration of FLVCR1; GAPDH loading control shown
- 561 below.
- 562 F) Immunostaining of WT or hFLVCR1 mutants overexpressed in HEK293 cells. Vertical yellow
- 563 horizontal bar shows image scale. Arrows (yellow) show plasma membrane, where membrane
- 564 GFP was used as a marker. Arrowheads show intracellular signals of hFLVCR1.
- 565

566 Web Resources

- 567 Online Mendelian Inheritance in Man, <u>http://www.omim.org</u>
- 568 gnomAD Browser, https://gnomad.broadinstitute.org/
- 569 Baylor College of Medicine Human Genome Sequencing Center, https://www.hgsc.bcm.edu
- 570 Baylor College of Medicine Lupski Lab, https://github.com/BCM-Lupskilab
- 571 CADD, https://cadd.gs.washington.edu/
- 572 SpliceAl and Pangolin, <u>https://spliceailookup.broadinstitute.org/</u>
- 573 primAD Browser, <u>https://primad.basespace.illumina.com/</u>
- 574

575 Data Availability

- 576 All data described in this study are provided within the article and Supplementary Material. Raw
- 577 sequencing data and de-identified clinical data are available from the corresponding authors
- 578 upon request.
- 579

580 Acknowledgements

581	This study was supported in part by the U.S. National Human Genome Research Institute
582	(NHGRI) and National Heart Lung and Blood Institute (NHBLI) to the Baylor-Hopkins Center for
583	Mendelian Genomics (BHCMG, UM1 HG006542, J.R.L); NHGRI grant as part of the GREGoR
584	Consortium (U01 HG011758 to J.E.P., J.R.L., and R.A.G.); NHGRI grant to Baylor College of
585	Medicine Human Genome Sequencing Center (U54HG003273 to R.A.G.); U.S. National
586	Institute of Neurological Disorders and Stroke (NINDS) (R35NS105078 to J.R.L); Muscular
587	Dystrophy Association (MDA) (512848 to J.R.L.); Singapore Ministry of Education grants
588	(T2EP30221-0012, T2EP30123-0014, and NUHSRO/2022/067/T1 to L.N.N.); and Spastic
589	Paraplegia Foundation Research Grant to J.R.L. D.P. was supported by a NINDS 1K23
590	NS125126-01A1 and Rett Syndrome Research Trust fellowship award from International Rett
591	Syndrome Foundation (IRSF grant #3701-1). D.G.C. was supported by NIH Medical Genetics
592	Research Fellowship Program (T32 GM007526), the Chao Physician Scientist Award, the Child
593	Neurologist Career Development Program K12, and MDA Development Grant (873841). K.M.B
594	was supported by the GREGoR Consortium Research Grant from the GREGoR Data
595	Coordinating Center (U24HG011746 to KMB); Foundation Fighting Blindness (EGI-GE-1218-
596	0753-UCSD to KMB), Iraty Award 2023, Lions Foundation, Research to Prevent Blindness, and
597	NEI: P30EY014104 (MEEI core support).

598

599 Ethics Declaration

600 This study adheres to the principles in the Declaration of Helsinki. The study was approved by

601 Baylor College of Medicine Institutional Review Board (IRB) protocol H-29697. Informed

602 consent including consent to have the results of this research work published was obtained from

all participants as required by the IRB.

604

605 Potential Conflict of Interest

- 506 J.R.L. has stock ownership in 23andMe, is a paid consultant for Genome International, and is a
- 607 co-inventor on multiple United States and European patents related to molecular diagnostics for
- 608 inherited neuropathies, eye diseases, genomic disorders, and bacterial genomic fingerprinting.
- 609 The Department of Molecular and Human Genetics at Baylor College of Medicine receives
- 610 revenue from clinical genetic testing conducted at Baylor Genetics (BG) Laboratories. Other
- 611 authors have no potential conflicts to disclose.
- 612

613 References:

- Pizzagalli MD, Bensimon A, Superti-Furga G. A guide to plasma membrane solute carrier proteins. *FEBS J.* 2021;288(9):2784-2835. doi:10.1111/febs.15531
- Marafi D, Fatih JM, Kaiyrzhanov R, et al. Biallelic variants in SLC38A3 encoding a glutamine
 transporter cause epileptic encephalopathy. *Brain*. 2022;145(3):909-924.
 doi:10.1093/brain/awab369
- Saida K, Maroofian R, Sengoku T, et al. Brain monoamine vesicular transport disease
 caused by homozygous SLC18A2 variants: A study in 42 affected individuals. *Genet Med.* 2023;25(1):90-102. doi:10.1016/j.gim.2022.09.010
- Kenny TC, Khan A, Son Y, et al. Integrative genetic analysis identifies FLVCR1 as a
 plasma-membrane choline transporter in mammals. *Cell Metab.* 2023;35(6):1057-1071.e12.
 doi:10.1016/j.cmet.2023.04.003
- 5. Klepper J, Akman C, Armeno M, et al. Glut1 Deficiency Syndrome (Glut1DS): State of the
 art in 2020 and recommendations of the international Glut1DS study group. *Epilepsia Open*.
 2020;5(3):354-365. doi:10.1002/epi4.12414
- 628 6. O'Callaghan B, Bosch AM, Houlden H. An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin transporter deficiency. *J Inherit Metab Dis*.
 630 2019;42(4):598-607. doi:10.1002/jimd.12053
- 631 7. Mathiesen BK, Miyakoshi LM, Cederroth CR, et al. Delivery of gene therapy through a
 632 cerebrospinal fluid conduit to rescue hearing in adult mice. *Sci Transl Med.*633 2023;15(702):eabq3916. doi:10.1126/scitranslmed.abq3916
- Tailor CS, Willett BJ, Kabat D. A putative cell surface receptor for anemia-inducing feline
 leukemia virus subgroup C is a member of a transporter superfamily. *J Virol.* 1999;73(8):6500-6505. doi:10.1128/JVI.73.8.6500-6505.1999

- 637 9. Chiabrando D, Marro S, Mercurio S, et al. The mitochondrial heme exporter FLVCR1b
 638 mediates erythroid differentiation. *J Clin Invest.* 2012;122(12):4569-4579.
 639 doi:10.1172/JCI62422
- 640 10. Quigley JG, Yang Z, Worthington MT, et al. Identification of a human heme exporter that is 641 essential for erythropoiesis. *Cell*. 2004;118(6):757-766. doi:10.1016/j.cell.2004.08.014
- Keel SB, Doty RT, Yang Z, et al. A heme export protein is required for red blood cell differentiation and iron homeostasis. *Science*. 2008;319(5864):825-828.
 doi:10.1126/science.1151133
- Ponka P, Sheftel AD, English AM, Scott Bohle D, Garcia-Santos D. Do Mammalian Cells
 Really Need to Export and Import Heme? *Trends Biochem Sci.* 2017;42(5):395-406.
 doi:10.1016/j.tibs.2017.01.006
- 13. Tsuchiya M, Tachibana N, Nagao K, Tamura T, Hamachi I. Organelle-selective click labeling
 coupled with flow cytometry allows high-throughput CRISPR screening of genes involved in
 phosphatidylcholine metabolism. Published online April 18, 2022:2022.04.18.488621.
 doi:10.1101/2022.04.18.488621
- 14. Ha HTT, Sukumar VK, Chua JWB, et al. Mfsd7b facilitates choline transport and missense
 mutations affect choline transport function. *Cell Mol Life Sci.* 2023;81(1):3.
 doi:10.1007/s00018-023-05048-4
- Son Y, Kenny TC, Khan A, Birsoy K, Hite RK. Structural basis of lipid head group entry to
 the Kennedy pathway by FLVCR1. *BioRxiv Prepr Serv Biol*. Published online September 28,
 2023:2023.09.28.560019. doi:10.1101/2023.09.28.560019
- 16. Ri K, Weng TH, Cabezudo AC, et al. Structural and mechanistic insights into human choline
 and ethanolamine transport. Published online December 19, 2023:2023.09.15.557925.
 doi:10.1101/2023.09.15.557925
- 661 17. Da Costa L, Leblanc T, Mohandas N. Diamond-Blackfan anemia. *Blood*.
 662 2020;136(11):1262-1273. doi:10.1182/blood.2019000947
- 18. Rey MA, Duffy SP, Brown JK, et al. Enhanced alternative splicing of the FLVCR1 gene in
 Diamond Blackfan anemia disrupts FLVCR1 expression and function that are critical for
 erythropoiesis. *Haematologica*. 2008;93(11):1617-1626. doi:10.3324/haematol.13359
- Rajadhyaksha AM, Elemento O, Puffenberger EG, et al. Mutations in FLVCR1 cause
 posterior column ataxia and retinitis pigmentosa. *Am J Hum Genet*. 2010;87(5):643-654.
 doi:10.1016/j.ajhg.2010.10.013
- Kuehlewein L, Schöls L, Llavona P, et al. Phenotypic spectrum of autosomal recessive
 retinitis pigmentosa without posterior column ataxia caused by mutations in the FLVCR1
 gene. *Graefes Arch Clin Exp Ophthalmol.* 2019;257(3):629-638. doi:10.1007/s00417-01804233-7
- 673 21. Chiabrando D, Castori M, di Rocco M, et al. Mutations in the Heme Exporter FLVCR1
 674 Cause Sensory Neurodegeneration with Loss of Pain Perception. *PLoS Genet*.
 675 2016;12(12):e1006461. doi:10.1371/journal.pgen.1006461

- Calame DG, Guo T, Wang C, et al. Monoallelic variation in DHX9, the gene encoding the
 DExH-box helicase DHX9, underlies neurodevelopment disorders and Charcot-Marie-Tooth
 disease. *Am J Hum Genet*. 2023;110(8):1394-1413. doi:10.1016/j.ajhg.2023.06.013
- Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for
 connecting investigators with an interest in the same gene. *Hum Mutat.* 2015;36(10):928930. doi:10.1002/humu.22844
- Wohler E, Martin R, Griffith S, et al. PhenoDB, GeneMatcher and VariantMatcher, tools for
 analysis and sharing of sequence data. *Orphanet J Rare Dis.* 2021;16(1):365.
 doi:10.1186/s13023-021-01916-z
- 685 25. Coban-Akdemir Z, Song X, Ceballos FC, et al. De novo mutation and identity-by-descent
 686 drive disease haplotypes, biallelic traits and multilocus pathogenic variation. Published
 687 online July 27, 2022:2020.04.27.064824. doi:10.1101/2020.04.27.064824
- 688 26. AlAbdi L, Shamseldin HE, Khouj E, et al. Beyond the exome: utility of long-read whole
 689 genome sequencing in exome-negative autosomal recessive diseases. *Genome Med.*690 2023;15(1):114. doi:10.1186/s13073-023-01270-8
- 691 27. Vaughan DP, Costello DJ. Extending the phenotype of posterior column ataxia with retinitis
 692 pigmentosa caused by variants in FLVCR1. *Am J Med Genet A*. 2022;188(4):1259-1262.
 693 doi:10.1002/ajmg.a.62612
- 28. Li Z, Li Y, Chu X, et al. Novel mutations in FLVCR1 cause tremors, sensory neuropathy with
 retinitis pigmentosa. *Neuropathol Off J Jpn Soc Neuropathol*. Published online July 19,
 2023. doi:10.1111/neup.12936
- Shaibani A, Wong LJ, Wei Zhang V, Lewis RA, Shinawi M. Autosomal recessive posterior
 column ataxia with retinitis pigmentosa caused by novel mutations in the FLVCR1 gene. Int
 J Neurosci. 2015;125(1):43-49. doi:10.3109/00207454.2014.904858
- 30. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified
 from variation in 141,456 humans. *Nature*. 2020;581(7809):434-443. doi:10.1038/s41586020-2308-7
- 31. Brandes N, Goldman G, Wang CH, Ye CJ, Ntranos V. Genome-wide prediction of disease
 variant effects with a deep protein language model. *Nat Genet*. 2023;55(9):1512-1522.
 doi:10.1038/s41588-023-01465-0
- 32. Coban-Akdemir Z, White JJ, Song X, et al. Identifying Genes Whose Mutant Transcripts
 Cause Dominant Disease Traits by Potential Gain-of-Function Alleles. *Am J Hum Genet*.
 2018;103(2):171-187. doi:10.1016/j.ajhg.2018.06.009
- 33. Gao H, Hamp T, Ede J, et al. The landscape of tolerated genetic variation in humans and primates. *Science*. 2023;380(6648):eabn8153. doi:10.1126/science.abn8197
- 34. Suthar R, Sharawat IK, Eggermann K, et al. Hereditary Sensory and Autonomic
 Neuropathy: A Case Series of Six Children. *Neurol India*. 2022;70(1):231.
 doi:10.4103/0028-3886.338691

- 35. Karaca E, Posey JE, Akdemir ZC, et al. Phenotypic expansion illuminates multilocus
 pathogenic variation. *Genet Med.* 2018;20(12):1528-1537. doi:10.1038/gim.2018.33
- 36. Ha HTT, Sukumar VK, Chua JWB, et al. Mfsd7b facilitates choline uptake and missense
 mutations affect choline transport function. Published online September 30,
 2023:2023.09.30.560304. doi:10.1101/2023.09.30.560304
- 719 37. Zeisel SH, Klatt KC, Caudill MA. Choline. *Adv Nutr.* 2018;9(1):58-60.
 720 doi:10.1093/advances/nmx004
- 38. Vennemann FBC, Ioannidou S, Valsta LM, et al. Dietary intake and food sources of choline
 in European populations. *Br J Nutr.* 2015;114(12):2046-2055.
 doi:10.1017/S0007114515003700
- 39. May T, Caudill M, Manary M. Is There Enough Choline for Children in Food Aid? JAMA
 Pediatr. 2023;177(3):223-224. doi:10.1001/jamapediatrics.2022.5543
- 40. Ganz AB, Klatt KC, Caudill MA. Common Genetic Variants Alter Metabolism and Influence
 Dietary Choline Requirements. *Nutrients*. 2017;9(8):837. doi:10.3390/nu9080837
- 41. Patel D, Witt SN. Ethanolamine and Phosphatidylethanolamine: Partners in Health and
 Disease. Oxid Med Cell Longev. 2017;2017:4829180. doi:10.1155/2017/4829180
- 42. Zeisel SH, Niculescu MD. Perinatal choline influences brain structure and function. *Nutr Rev.* 2006;64(4):197-203. doi:10.1111/j.1753-4887.2006.tb00202.x
- 732 43. Trujillo-Gonzalez I, Friday WB, Munson CA, et al. Low availability of choline in utero disrupts
 733 development and function of the retina. *FASEB J*. 2019;33(8):9194-9209.
 734 doi:10.1096/fj.201900444R
- 44. Wang Y, Surzenko N, Friday WB, Zeisel SH. Maternal dietary intake of choline in mice
 regulates development of the cerebral cortex in the offspring. *FASEB J*. 2016;30(4):15661578. doi:10.1096/fj.15-282426
- 45. Alexander HD, Engel RW. The importance of choline in the prevention of nutritional edema in rats fed low-protein diets. *J Nutr*. 1952;47(3):361-374. doi:10.1093/jn/47.3.361
- 46. Zeisel SH, Da Costa KA, Franklin PD, et al. Choline, an essential nutrient for humans.
 FASEB J Off Publ Fed Am Soc Exp Biol. 1991;5(7):2093-2098.
- 47. May T, de la Haye B, Nord G, et al. One-carbon metabolism in children with marasmus and kwashiorkor. *EBioMedicine*. 2022;75:103791. doi:10.1016/j.ebiom.2021.103791
- 48. Wortmann SB, Mayr JA. Choline-related-inherited metabolic diseases—A mini review. J
 Inherit Metab Dis. 2019;42(2):237-242. doi:10.1002/jimd.12011
- 49. Barwick KES, Wright J, Al-Turki S, et al. Defective presynaptic choline transport underlies
 hereditary motor neuropathy. *Am J Hum Genet*. 2012;91(6):1103-1107.
 doi:10.1016/j.ajhg.2012.09.019

- 50. Bauché S, O'Regan S, Azuma Y, et al. Impaired Presynaptic High-Affinity Choline
 Transporter Causes a Congenital Myasthenic Syndrome with Episodic Apnea. *Am J Hum*
- 751 *Genet.* 2016;99(3):753-761. doi:10.1016/j.ajhg.2016.06.033
- 51. Fagerberg CR, Taylor A, Distelmaier F, et al. Choline transporter-like 1 deficiency causes a new type of childhood-onset neurodegeneration. *Brain J Neurol.* 2020;143(1):94-111.
 doi:10.1093/brain/awz376
- 755 52. Nguyen XTA, Le TNU, Ha HTT, et al. MFSD7c functions as a transporter of choline at the
 blood-brain barrier. Published online October 3, 2023:2023.10.03.560597.
 doi:10.1101/2023.10.03.560597
- 53. Meyer E, Ricketts C, Morgan NV, et al. Mutations in FLVCR2 are associated with
 proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (Fowler
 syndrome). Am J Hum Genet. 2010;86(3):471-478. doi:10.1016/j.ajhg.2010.02.004
- 54. Wozniak JR, Fuglestad AJ, Eckerle JK, et al. Choline supplementation in children with fetal alcohol spectrum disorders: a randomized, double-blind, placebo-controlled trial. *Am J Clin Nutr.* 2015;102(5):1113-1125. doi:10.3945/ajcn.114.099168
- 55. Gimbel BA, Anthony ME, Ernst AM, et al. Long-term follow-up of a randomized controlled
 trial of choline for neurodevelopment in fetal alcohol spectrum disorder: corpus callosum
 white matter microstructure and neurocognitive outcomes. *J Neurodev Disord*.
 2022;14(1):59. doi:10.1186/s11689-022-09470-w
- 56. Mercurio S, Petrillo S, Chiabrando D, et al. The heme exporter Flvcr1 regulates expansion
 and differentiation of committed erythroid progenitors by controlling intracellular heme
 accumulation. *Haematologica*. 2015;100(6):720-729. doi:10.3324/haematol.2014.114488
- 57. Inoue K, Khajavi M, Ohyama T, et al. Molecular mechanism for distinct neurological
 phenotypes conveyed by allelic truncating mutations. *Nat Genet*. 2004;36(4):361-369.
 doi:10.1038/ng1322
- 58. Neu-Yilik G, Amthor B, Gehring NH, et al. Mechanism of escape from nonsense-mediated
 mRNA decay of human β-globin transcripts with nonsense mutations in the first exon. *RNA*.
 2011;17(5):843-854. doi:10.1261/rna.2401811
- 777

778

779

780

781

782

784
785
786
787
788
789
790
791
792
793
794

Table 1:	Phenotypic	summary o	f individuals	with FLVCR	1-related dev	elopmental a	nd neurodeg	enerative dis	sorders
	Family 1	Family 2	Family 3	Family 4	Family 5	Fam	nily 6	Family 7	Family 8
	Individual 1	Individual 2	Individual 3	Individual 4	Individual 5	Individual 6	Individual 7	Individual 8	Individual 9
Sex, ethnicity	M, S. Asia	M, Middle East	M, European	M, S. Asia	M, North Africa	M, Middle East	M, Middle East	F, S. Asia	F, European
Age at last exam Age at death	6-10 yo NA	0-5 yo 0-5 yo	6-10 yo NA	0-5 yo 0-5 yo	0-5 yo 0-5 yo	NA 0-5 vo	6-10 yo NA	6-10 yo NA	0-5 yo 0-5 yo
Nucleotide	c.1390G>A	c.1328T>G	c.1169T>G / c.1261G>A	c.153_154insC	c.915T>G	c.1235G>C ¹	c.1235G>C	c.1390G>A	c.1019C>T / c.1225T>C
Protein	p.G464S	p.L443P	p.L390* / p.D421N	p.A52Rfs*38	p.S305R	p.G412A ¹	p.G412A	p.G464S	p.T340I / p.S409P
Phenotypic category	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD
Microcephaly	+	+	+	+	+		+	+	+
(Z-score)	(-2.5)	(-4.2)	(-9.0)	(-6.5)	(-10.5)	+	(-5.6)	(-4.7)	(-2.9)
DD/ID	Profound	Profound	Profound	Profound	Profound	Profound	Profound	Profound	Profound
Cortical visual impairment	+	-	+	+	+	-	-	-	Unk
Optic disk atrophy	+	+	+	+	+	-	-	-	Unk
Retinitis pigmentosa	-	-	+	-	-	-	-	+	Unk
Hypotonia	+	+	-	+	+	+	+	+	+
Self-mutilation	+	-	-	-	-	-	-	+	-
Osteomyelitis	+	-	-	-	-	-	-	+	-
Sensory neuropathy	+	-	-	-	-	-	-	+	Unk
Motor neuropathy	-	-	-	+	-	-	-	-	Unk
Scoliosis	+	-	+	-	-	-	-	-	Unk
Spasticity	-	+	+	-	+	+	+	-	+
Dystonia	-	-	-	-	+	-	-	-	-
Epilepsy	+	+	+	-	+	+	+	+	Unk
Reduced brain volume	+	+	+	+	+	+	+	+	+
Macrocytic anemia	-	-	-	+	-	-	-	+	Unk
Craniofacial malformations	-	-	-	-	-	-	-	-	-
Limb & digital malformations	-	-	-	+	-	-	-	-	-
Other clinical features			Chorea, myoclonus, pain insensitivity, restrictive LD, neurogenic bladder, severe OSA	Thin corpus callosum, hepatomegaly, preaxial polydactyly, recurrent UTI				Complex IV deficiency on muscle RCE, low CSF 5- MTHF	Laryngomalacia

not done; Unk, unknown; LD, lung disease; OSA, obstructive sleep apnea; UTI, urinary tract infections; CSA, central sleep apnea; RCE, respiratory chain enzymes; 5-MTHF – 5methyltetrahydrofolate; 1,2 – patient DNA not available for genotyping but felt to have same condition.

	Fam	nily 8		Family 9		Family 10	Family 11	Family 12
	Individual 10	Individual 11	Individual 12	Individual 13	Individual 14	Individual 15	Individual 16	Individual 17
Sex, ethnicity	F, European	F, European	F, Middle East	M, Middle East	M, Middle East	F, N. Africa	F, European	M, Middle East
Age at last exam	0-5 уо	0-5 уо	NA	NA	NA	0-5 yo	0-5 yo	NA
Age at death	0-5 yo	0-5 уо	Stillborn	Stillborn	Stillborn	0-5 yo	0-5 yo	Neonatal period
Nucleotide	c.1019C>T / c.1225T>C	c.1019C>T / c.1225T>C	c.1593+5_1593+8del ²	c.1593+5_1593+8del	c.1593+5_1593+8del ²	c.215dupC	c.1198C>T/ c.884-3C>G	c.1089T>G
Protein	p.T340I / p.S409P	p.T340I / p.S409P	p.? ²	p.?	p.? ²	p.E74Rfs*16	p.Q400* / p.?	p.Y363*
Phenotypic category	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD =
Microcephaly (Z-score)	+ (-6.0)	+ (-3.4)	+	+	+	+ (-3.6)	+ (-3.9)	+ made
DD/ID	Profound	Profound	NA	NA	NA	Profound	Profound	NA a
Cortical visual impairment	+	+	NA	NA	NA	-	+	NA allable
Optic disk atrophy	+	-	NA	NA	NA	+	+	NA unde
Retinitis pigmentosa	Unk	+	NA	NA	NA	-	-	NA a
Hypotonia	+	+	NA	NA	NA	+	+	NA 👸
Self- mutilation	-	-	NA	NA	NA	-	+	NA 4
Osteomyelitis	-	-	NA	NA	NA	-	-	NA 📑
Sensory neuropathy	Unk	Unk	NA	NA	NA	+	-	NA natio
Motor neuropathy	Unk	Unk	NA	NA	NA	+	-	NA <u>a</u>
Scoliosis	+	+	NA	NA	NA	-	+	NA 👸
Spasticity	+	+	NA	NA	NA	-	-	NA ."
Enilensy	+	-	NA	NA NA	NA NA	-	+	
Reduced brain volume	+	+	+	+	+	+	+	+
Macrocytic anemia	+	+	Unk	Unk	Unk	-	+	Unk
Craniofacial malformations	-	-	+	+	+	-	-	+
Limb & digital malformations	-	-	+	+	+	+	+	+
Other clinical features	Laryngomalacia, hypothyroidism, CSA	Laryngomalacia, OSA, hypothyroidism				Elevated creatine kinase	B cell lymphopenia, anemia, bifid right thumb, bilateral fixed	Hepato- splenomegaly, cardiomegaly, renal agenesis

								talipes, chronic lung disease		(w
Abbreviations: done; Unk, u	NDD, neurode nknown; LD, lur	velopmental disor ng disease; OSA, methyltetra	rder; yo, years old; obstructive sleep a ahydrofolate; 1,2 –	mo, months old; DOL pnea; UTI, urinary tra patient DNA not avai	, day of life; DD/ID, d act infections; CSA, ce lable for genotyping b	evelopmental delay, entral sleep apnea; out felt to have same	/intellectual disabili RCE, respiratory c e condition.	ity; NA, not appli hain enzymes; 5	cable; ND, not -MTHF – 5-	hich was not
	Fam	nihy 13	Family 14	Family 15	Family 16	Fami	ily 17	Family 18	Family 10	certifi
	Individual	Individual 19		Individual 21	Individual 22	Individual 23	Individual 24	Individual 25		
	18						marviauai 24			
Sex, ethnicity	M, Middle East	F, Middle East	F, N. Africa	M, Middle East	M, Middle East	M, North Africa	M, North Africa	F, Middle East	F, Middle East	eer ro
Age at last exam	6-10 yo	0-5 уо	11-15 уо	11-15 уо	41-45 yo	6-10 yo	6-10 yo	31-35 yo	0-5 yo	<u> </u>
Age at death	NA	NA	NA	NA	NA	NA	NA	NA	NA	s m
Nucleotide	c.1028T>C	c.1028T>C	c.1_18del	c.382T>A	c.382T>A	c.757T>G	c.757T>G	c.502C>G	c.574T>C	is i
Protein	p.I343T	p.I343T	p.M1_D6del	p.Y128N	p.Y128N	p.F253V	p.F253V	p.L168V	p.C192R	e a
Phenotypic category	Mild	Mild	Mild	Mild	Mild	Mild	Mild	Mild	Mild	authovailab
Microcephaly (Z-score)	-	-	-	-	-	+ (-5.5)	+ (-5.6)	-	-	or/func
DD/ID	-	-	Mild ID	-	-	Moderate ID	Severe ID	-	Mild DD	der,
Cortical visual impairment	-	-	-	-	-	-	-	-	-	who
Optic disk atrophy	-	-	-	-	-	-	-	-	-	has gr BY 4.
Retinitis pigmentosa	-	-	+	+	+	-	-	+	-	anted 0 Inte
Hypotonia	-	-	+	-	+	+	+	-	+	me
Self-mutilation	-	-	+	-	-	-	-	-	+	G Å
Osteomyelitis	-	-	+	-	-	-	-	-	-	a Xiv
Sensory neuropathy	+	+	+	+	-	-	-	+	+	a licei icense
Motor neuropathy	-	-	+	+	+	-	-	-	-	nse to
Scoliosis	-	-	-	-	+	-	+	-	-	dis
Spasticity	-	-	-	-	+	-	-	-	-	pla
Dystonia	-	-	-	+	-	-	-	-	-	y t
Epilepsy	-	-	-	-	-	-	+	-	-	e C
Reduced brain volume	ND	ND	-	ND	ND	+	+	ND	ND	preprir
Macrocytic anemia	-	-	-	-	-	-	-	-	-	it in p
Craniofacial malformations	-	-	-	-	-	-	-	-	-	erpetu
Limb & digital malformations	-	-	-	-	-	-	-	-	-	lity.
Other clinical					Progressive	Dysmorphic	Dysmorphic			

features				spastic paraplegia, childhood onset	facies, autistic features	facies, autistic features,		
Abbraviationa	IDD nourodovolonm	antal diaardari ya ya	ldi ma mantha aldi DOL	day of life, DD/ID, day	alanmantal dalav/ir	cryptorchidism	"NA not opplie	able: ND not
reportedND not d	lono: Unk unknown:	L D lung disease: OS	ia, mo, montris ola, DOL,	TL uripary tract infactio	elopmental delay/in		, NA, NOL applica	able, NR, not
reporteund, not u	MTH	ED, lung uisease, OS = _ 5-methyltetrahydr	te $1.2 - \text{patient DNA not}$	available for genotypin	a but felt to have s	eep apried, ROE, reprint a condition	espiratory chain	enzymes, 5-
	101111		10, 1, 2 - patient DNA not	available for genotypin	y but left to have s			
	Family 20	Severe NDD						
	Individual 27	Summary						
Sex ethnicity	F Middle East	ourninary						
Age at last exam	66-70 vo							
Age at death	NA	13/17						
Nucleotide	c.1028T>C							
Protein	p. 343T							
Phenotypic	N 4'' 1							
category	Mild							
Microcephaly		17/17						
(Z-score)	-	1//1/						
DD/ID	-	13/13						
Cortical visual	_	7/12						
impairment		1112						
Optic disk	_	8/12						
atrophy		0/12						
Retinitis	+	3/12						
pigmentosa		40/40						
Hypotonia	-	12/13						
Self-mutilation	-	3/12						
Osteomyelitis	-	2/12						
Sensory	-	3/10						
Motor								
neuronathy	-	2/10						
Scoliosis		5/12						
Spasticity	-	8/13						
Dystonia	+	3/13						
Epilepsy	-	11/12						
Reduced brain		4-1/-						
volume	-	17/17						
Macrocytic		E/40						
anemia	-	5/12						
Craniofacial	_	A/17						
malformations	-							
Limb & digital	_	7/17						
malformations		.,						
Other clinical								
features								
Abbreviations: N	DD, neurodevelopme	ental disorder; yo,						
years old; mo, r	nonths old; DOL, day	of life; DD/ID,						
developmental	delay/intellectual disa	adility; NA, hot						

applicable; ND, not done; Unk, unknown; LD, lung disease;
OSA, obstructive sleep apnea; UTI, urinary tract infections;
CSA, central sleep apnea; RCE, respiratory chain enzymes;
5-MTHF – 5-methyltetrahydrofolate; 1,2 – patient DNA not available for genotyping but felt to have same condition.

Table 2: Summary of FLVCR1 variant alleles									
Individual(s)	Phenotype	Zygosity	Position (hg19)	Nucleotide / Protein	Allele count / frequency (anomAD)	CADD	REVEL	phylop100 way	SpliceAl
F1, I-1; F7, I-8	Severe	Hmz	1-213061913-G-A	c.1390G>A p.G464S	1 htz 1 in 251,426	33	0.742	9.242	0.17 (donor gain), 0.23 (donor loss)
F2, I-2	Severe	Hmz	1-213061851-T-G	c.1328T>G p.L443P	0	31	0.757	7.546	0.11 (donor gain)
F3, I-3	Severe	Cmp htz	1-213058711-T-G	c.1169T>G p.L390*	0	37	-	7.546	0
	Severe	Cmp htz	1-213061297-G-A	c.1261G>A p.D421N	0	16.72	0.087	-0.223	0.22 (donor loss)
F4, I-4	Severe	Hmz	1-213031948C	c.153_154insC p.A52Rfs*38	0	-	-	5.239	- ma
F5, I-5	Severe	Hmz	1-213046051-T-G	c.915T>G p.S305R	0	23.1	0.486	0.23	0 average of the second
F6, I-7	Severe	Hmz	1-213061271-G-C	c.1235G>C p.G412A	2 htz 1 in 125,477	29.8	0.435	4.104	0.11 (acceptor gain), 0.28 (acceptor loss) c
F8, I-9, I-10, I-11	Severe	Cmp htz	1-213046155-C-T	c.1019C>T p.T340I	2 htz 1 in 125,435	22.5	0.281	0.814	
	Severe	Cmp htz	1-213061261-T-C	c.1225C>T p.S409P	0	29.5	0.624	5.727	0.19 (acceptor 2 gain)
F9, I-12 ^a , I-13, I-14 ^a	Severe	Hmz	1-213068396-GTAA-	c.1593+5_1593+8del, p.?	9 htz 1 in 27,874	-	-	7.236	جې ۵.97 (donor loss)
F10, I-15	Severe	Hmz	1-213032009C	c.215dupC, p.E74Rfs*16	0	-	-	5.549	- Intern
F11, I-16	Severe	Cmp htz	1-213061234-C-T	c.1198C>T p.Q400*	0	47	-	3.853	0 ationa
		Cmp htz	1-213046017-C-G	c.884-3C>G p.?	0	17.84	-	0.123	0.43 (acceptor is a loss), 0.09 (acceptor gain)
F12, I-7	Severe	Hmz	1-213056777-T-G	c.1089T>G p.Y363*	0	34	-	0.449	0.02 (donor loss)
F13, I-18, I-19; F20, I-27	Mild	Hmz	1-213056716-T-C	c.1028T>C p.I343T	1 htz 1 in 242.226	26.9	0.525	6.637	0
F14, I-20	Mild	Hmz	1-213031792- GATATGGCGCGGCCAGAC-	c.1_18del p.?	0	-	-	3.118	- 5
F15, I-21; F16, I-22	Mild	Hmz	1-213032176-T-A	c.382T>A p.Y128N	0	32	0.723	7.629	0
F17, I-23, I-24	Mild	Hmz	1-213037085-T-G	c.757T>G p.F253V	0	29.8	0.718	7.806	
F18, I-25	Mild	Hmz	1-213032296-C-G	c.502C>G p.L168V	0	26.0	0.34	3.743	0 .
F19, I-26	Mild	Hmz	1-213032368-T-C	c.574T>C	5 htz 1 in 50 112	29.3	0.895	1.93	0

Abbreviations: CADD, Combined Annotation Dependent Depletion GRCh37-v1.6; gnomAD, Genome Aggregation Database v2.1.1; hmz, homozygote; cmp htz, compound heterozygote; REVEL, rare exome variant ensemble learner; a – patient DNA not available for genotyping but felt to have same condition.

Fig. 2







